This morning at #CoronaryComplications During PCI: A Case-Based Learning Opportunity!🫀

Faculty includes kamal chitkara curzen Dr.Ahmed Ayuna Vinoda Sharma #WIC Mina Fares Shazia T Hussain Mohaned Egred Sandeep Basavarajaiah Abdul Mozid Javed Ahmed Farzin Ordoubadi Shamim Rahman Elif Ezgi Ustun and

Hybrid IVUS-OCT systems can overcome the limitations associated with each technology and integrate the advantages of both modalities. Recently, a novel hybrid imaging system (PANOVISION) was approved for clinical use and tested in this noniferiority trial. #EIJBestOf

Reducing Door to Balloon 🎈 time, Self driving Tesla takes a man with Heart Attack, 17 miles fm his home to ER. Sunil V. Rao Mamas A. Mamas Hany Ragy Dr. Purvi Parwani Salvatore Brugaletta PCRonline 🫀 Radcliffe Cardiology Dr Shariq Shamim Beth Frates MD Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Goran Stankovic, MD, PhD Elon Musk

Final poll results: with 677 responses, after PREVENT, 35% are ready to treat non-flow-limiting asymptomatic vulnerable plaques with preventive PCI to improve prognosis. 65% are not yet believers. 4 other trials are ongoing and more are being designed.

The National audit report NICOR UK in PCI published today: nicor.org.uk/interactive-re…

Thank you to my team in helping to delivering this particularly Pete Jones. Whilst intracoronary imaging rates continue to increase, Prasugrel use in ACS PCI remains poor, and delays of

Can we trust the findings of the PREVENT trial, just published in The Lancet? To be very frank, I am not sure... Is it remotely credible a trial in which PCI with DES perfomed in high-risk lesions yields a cumulative 2-year rate of cardiac death, MI, TVR, or hospitalisation for

Despite clear rationale…Routine physiology using pressure wire has not been beneficial across stable or acs patients now in RIPCORD2, FUTURE, FAME3, FLOWER & here. FAMOUS did show benefit….. there is so much we don’t understand!?

Powerful 📝on stress echo E/e’
on 14,338 patients Mayo Clinic CV

poststress E/e’ ≥15
2.71-fold ⬆️☠️rate/10yrs 🆚 poststress E/e’ of ≤8

1,323 (9.2%)w exercise⬆️in LV FPs & majority (6%)w⬆️post exercise LV FPs did NOT have exercise-induced RWMAs

bit.ly/3Rb74dV

A glimpse into the future of medicine?

In a study including 508 patients with myocardial ischemia with no obstructive coronary arteries undergoing invasive coronary function testing with CBF, CFR, and IMR assessment, slow flow as defined with a cTFC >25 was poorly associated with results of invasive coronary function

Just fascinating

Download slides for PREVENT trial on PCI + OMT in reducing MACE in non-flow-limiting vulnerable plaques. Link here: shorturl.at/ijqAM

#ORBITA -COSMIC Rasha Al-Lamee John Foley presents at #ACC24

In refractory angina patients an CS occluder device shows improved subendocardial perfusion by stress #WhyCMR (not transmural) and reduces
angina frequency & improved QOL 🆚 placebo bit.ly/3TSC3vo

I think now that the BCIS group has made consensus for OHCA we are now in a position to tackle CGS and learn from yours and others experience. We should reconvene BCIS group curzen Nilesh Pareek John Davies Tom Quinn etc. Tom Johnson Paul Rees Ellie Gudde Abdul Mozid

ORBITA - COSMIC found CSR reduced angina compared to placebo

⁦Rasha Al-Lamee⁩ ⁦Mamas A. Mamas⁩ ⁦Dr Shrilla Banerjee MD FRCP 💙⁩ ⁦MedShr⁩ ⁦curzen ⁩ thelancet.com/journals/lance…

Nuts are a superfood

I encourage all my patients to eat nuts

Yet more evidence showing this is wise

nejm.org/doi/full/10.10…

Some may debate the CI that goes from 0.79-1.16, but, clinically, we have to draw the line of ... this is negative not underpowered somewhere

For me, I am happy to stop prescribing beta-blockers postMI

I know; it's a frequentist analysis. But the priors are very pessimistic.

Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction | New England Journal of Medicine nejm.org/doi/full/10.10…

Congrats to the authors for life saving research! 🚀 What an accomplishment 👏
RigsHeart 🫀🚨 NEJM Thomas Engstrøm Christian Hassager

In the DanGer Shock randomized trial, including 360 patients with STEMI complicated by cardiogenic shock, Impella reduced 180-day all-cause death from 59% to 46% (p=0.04, NNT=8), and a composite endpoint of escalation of treatment to additional MCS, heart transplantation, or